Health TrialsbyHealthPanel

Feru-guard and General Antioxidant Capacity in Older People

ConditionHealthy Elder People
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65-89
SponsorOregon Health and Science University

About this trial

To determine if Feru-guard, a dietary supplement, can decrease general oxidation and inflammation in people who are ages 65-89 years old. Also to determine if Feru-guard is safe in older people when given for 3 months.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

65 to 89 years old

Not demented or mild cognitive impairment, defined as Clinical Dementia Rating (CDR) =0 and MMSE >24.

Informant has direct contact with participant at least 2 days per week to verify functional status, CDR, and accompany participant to in-clinic screening visit

Sufficient English language skills to complete all testing.

Disqualifiers

Any dementing illness (AD, vascular dementia, normal pressure hydrocephalus, or Parkinson's disease); dementia defined by CDR ≥ 0.50, MMSE < 25

AD medication (e.g. acetylcholinesterase inhibitors, NMDA receptor agonist, disease-modifying monoclonal antibody immunotherapy (e.g. lecanemab))

Significant disease of the CNS such as brain tumor, seizure disorder, subdural hematoma, cranial arteritis

Alcohol or substance abuse according to DSM-IV criteria within the last 2 years

Trial design

Design model

Parallel

Treatments tested in this trial

  • Feru-guard

    Dietary supplement

    Ferulic acid and Angelica dietary supplement in capsules

  • Placebo

    Other intervention

    Placebo capsules

Treatment groups

70 Participants
are divided into 2 treatment groups
Group A: Feru-guardExperimental treatment 1 intervention
Group B: Placebo GroupPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Anti-oxidant Measure

general oxidative stress marker malondialdehyde (MDA),

Time frame
12 Weeks
2

general oxidative stress marker malondialdehyde (MDA),

Time frame
12 weeks
3

Anti-inflammatory measure

an inflammatory marker tumor necrosis factor alpha (TNF-alpha).

Time frame
12 weeks

Secondary outcomes

1

Adverse Events

Adverse Event Report

Time frame
12 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Oregon Health and Science University

Lead sponsor

Glovia Co., Ltd.

Collaborator

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: